Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will have a ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped patients lose weight while preserving lean muscle mass in a mid-stage ...

Regeneron also said it will license an experimental obesity drug from China's Hansoh Pharmaceuticals (3692.HK), opens new tab in a deal worth up to $2.01 billion. Weight-loss drugs from current ...